Potential Weak Interaction
Quality of Evidence:
Coadministration has not been studied. In vitro studies suggest that sulfadiazine is partly metabolized by CYP2C9. In vivo data indicate that ritonavir is a modest inducer of CYP2C9 when used as a pharmacokinetic booster and may decrease levels of sulfadiazine to a moderate extent. The clinical significance of this potential interaction is unknown.
View all available interactions with
Ritonavir (RTV) by clicking